Efficacy of single-pill perindopril/indapamide in patients with hypertension and type 2 diabetes

High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension
T A NetchessovaNIKA Study Group

Abstract

Hypertension and type 2 diabetes in combination are associated with a significantly higher level of cardiovascular events. The aim of this prospective study was to evaluate the antihypertensive efficacy and tolerability of single-pill perindopril/indapamide in patients with hypertension and type 2 diabetes. Patients with both hypertension and type 2 diabetes were enrolled in this multicenter, prospective, open clinical study. Single-pill perindopril/indapamide was either prescribed on its own (started or switched to from previous treatment) or added to previous therapy. Perindopril/indapamide dosage could be increased, from 5/1.25 mg to 10/2.5 mg once daily, if blood pressure (BP) was uncontrolled. BP and tolerability were assessed at 4 visits over a 6-month period. Microalbuminuria was assessed at baseline and 6 months in a subgroup. 397 patients were analyzed (age 57.6 ± 9.4 years, men 46 %). At baseline, systolic blood pressure (SBP) was 160.0 ± 14.3 mmHg, diastolic blood pressure (DBP) 95.2 ± 8.3 mmHg, and pulse pressure 64.8 ± 12.7 mmHg. Nearly half (45 %) of patients received perindopril/indapamide alone and 55 % added this single-pill combination to existing therapy. After 6 months, SBP fell by 30 mmHg, DBP by 14 mmHg, a...Continue Reading

References

Oct 6, 2004·Seminars in Dialysis·Jaime Uribarri, UNKNOWN National Kidney Foundation
Apr 13, 2005·Lancet·Michael StumvollTimon W van Haeften
Jun 15, 2007·European Heart Journal·Giuseppe Mancia The task force for the management of arterial hypertension of the European Society of Cardiology
Sep 1, 2007·Journal of Hypertension·Giuseppe ManciaUNKNOWN ESH-ESC Task Force on the Management of Arterial Hypertension
Apr 2, 2008·The New England Journal of Medicine·Nigel S BeckettUNKNOWN HYVET Study Group
May 16, 2009·Journal of the American Society of Nephrology : JASN·Toshiharu NinomiyaUNKNOWN ADVANCE Collaborative Group
Jun 9, 2009·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·Luis M Ruilope, Julian Segura
May 27, 2010·European Heart Journal·Hiddo J Lambers HeerspinkUNKNOWN ADVANCE Collaborative Group
Mar 30, 2011·European Heart Journal·Luis M Ruilope, George L Bakris
Sep 29, 2011·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Daniel Pella
Nov 15, 2011·Journal of Hypertension·Cesar CerezoFranz H Messerli
Jan 31, 2012·Current Pharmaceutical Design·Giovanna LeonciniPontremoli Roberto
Jun 26, 2012·Expert Opinion on Pharmacotherapy·Bernard WaeberFrançois Feihl
Jan 31, 2013·Journal of the American Society of Nephrology : JASN·Maryam AfkarianIan H de Boer
Jun 12, 2013·Expert Review of Cardiovascular Therapy·Roberto Ferrari, Eric Boersma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.